Inhibiting Sickle Cell Adhesion via ERK1/2 Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sickle cell disease is characterized by vaso-occlusive phenomena and hemolytic anemia due to abnormal red blood cell adhesion to endothelial cells, which leads to severe complications and is not effectively addressed by existing treatments.
Innovation Solution
Administering MEK, ERK, or Raf inhibitors, such as U0126, RDEA119, or AEZS-131, to inhibit the adhesion of sickle red blood cells to endothelial cells, leukocytes, and the formation of multicellular aggregates, thereby reducing vaso-occlusion and associated symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for sickle cell disease, then general symptom management is provided, but vaso-occlusive phenomena and abnormal red blood cell adhesion are not effectively addressed
Solution Approach 1:
The patent changes the biochemical parameters of sickle red blood cells by inhibiting the ERK1/2 signaling pathway using specific inhibitors (U0126, RDEA119, AEZS-131). This parameter change in the signaling pathway activity reduces the adhesive properties of sickle cells, thereby addressing the harmful vaso-occlusive phenomena that existing treatments fail to effectively manage
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediary substances that mediate between the ERK1/2 signaling pathway and the adhesive behavior of sickle red blood cells. These inhibitors act as mediators to block the abnormal signaling that leads to excessive adhesion, providing a targeted mechanism to address vaso-occlusive phenomena
2Object-affected harmful factors
If MEK, ERK, or Raf inhibitors are administered to inhibit adhesion of sickle red blood cells, then vaso-occlusion is reduced, but the complexity of treatment increases
Solution Approach 1:
The patent extracts and targets the specific ERK1/2 signaling pathway from the complex network of cellular signaling mechanisms in sickle red blood cells. By isolating and inhibiting this particular pathway with specific small molecule inhibitors, the treatment addresses vaso-occlusion through a focused mechanism rather than requiring complex multi-target interventions
Solution Approach 2:
The patent employs small molecule inhibitors that can be administered systemically and act transiently to block the ERK1/2 pathway. These relatively simple chemical compounds provide temporary but effective inhibition of the adhesive signaling, offering a practical treatment approach that balances efficacy with administrative feasibility
Data Source
AI summary
Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, β-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from an ERK inhibitor, a MEK inhibitor, and, a Raf inhibitor. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells are also provided.